Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier

Oral delivery of peptide therapeutics faces multiple challenges due to their instability in the gastrointestinal tract and low permeation capability. In this study, the aim is to develop a liposomal nanocarrier formulation to enable the oral delivery of the vancomycin-peptide derivative FU002. FU002 is a promising, resistance-breaking, antibiotic which exhibits poor oral bioavailability, limiting its potential therapeutic use. To increase its oral bioavailability, FU002 is incorporated into tetraether lipid-stabilized liposomes modified with cyclic cell-penetrating peptides on the liposomal surface. This liposomal formulation shows strong binding to Caco-2 cells without exerting cytotoxic effects in vitro. Pharmacokinetics studies in vivo in rats reveal increased oral bioavailability of liposomal FU002 when compared to the free drug. In vitro and in vivo antimicrobial activity of FU002 are preserved in the liposomal formulation. As a highlight, oral administration of liposomal FU002 results in significant therapeutic efficacy in a murine systemic infection model. Thus, the presented nanotechnological approach provides a promising strategy for enabling oral delivery of this highly active vancomycin derivative. Cell penetrating peptide (CPP)-modified and glycerylcaldityl tetraether (GCTE)-stabilized liposomes are used to enable oral delivery of the vancomycin-conjugate FU002. Encapsulation of this novel antibiotic in CPP-GCTE liposomes results in improved oral bioavailability when compared to the free drug. Thus, this nanotechnological approach may improve oral drug delivery and enhance antibiotic therapy. image